Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Docetaxel and Bortezomib in Advanced Hormone-Refractory Prostate Cancer
NCT00193232Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- May 2004
- Primary completion
- Oct 2005
- Modality
- Small Molecules, Modified Peptides
01
Overview
A Phase 2 trial of bortezomib in prostate cancer (PCa), sponsored by SCRI Development Innovations. Started May 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00193232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193232.